teprotumumab

all catalysts(8)

News(7)

• Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
  Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future bus…
  biospace · 6d ago
• 7 companies hiring in New York now
  Looking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals like you.
  biospace · 13d ago
• Viridian may have edge over Amgen in eye drug showdown, analysts argue
  The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.
  biopharma_dive · 1mo ago
• Ethyreal starts up with $101M and takes aim at a pair of immune diseases
  The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
  biopharma_dive · 2mo ago
• Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
  Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…
  biopharma_dive · 2mo ago
• Viridian data lift prospects for thyroid eye disease drug
  Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
  biopharma_dive · 3mo ago
• Fierce Biotech Fundraising Tracker '26: Vaderis nets $152M series B; Epicrispr adds $90M
  The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
  fiercebiotech · 7mo ago